bradykinin B2 antagonist
Icatibant dose
Answer
FDA label for Firazyr: The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area. Trials with posted results tested 1 dose, most often 30 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
Firazyr NDA022150 · label of 2025-07-07 Regulator
The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.
Icatibant ANDA213773 · label of 2025-07-01 Regulator
The recommended dose of Icatibant injection is 30 mg administered by subcutaneous (SC) injection in the abdominal area.
SAJAZIR ANDA212446 · label of 2024-02-16 Regulator
The recommended dose of SAJAZIR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.
IN TRIALS
Doses tested in 15 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 30 mg | 1 | 60 | 3 |
Trial register Read from the titles of arms that received Icatibant (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.